Comparative Pharmacology
Head-to-head clinical analysis: CERINTA versus LYNORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERINTA versus LYNORAL.
CERINTA vs LYNORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.
LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.
50 mg orally twice daily
50 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 h) in adults; prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12–15 hours (11.2 ± 2.6 h in young adults; 14.8 ± 3.9 h in elderly), requiring once-daily dosing for steady-state within 4–7 days.
Renal (70% unchanged) and fecal (25% as metabolites); biliary excretion minimal (<5%).
Renal: ~50% as unchanged drug; ~20% as glucuronide conjugates. Biliary/fecal: ~30% (including enterohepatic recirculation).
Category C
Category C
Oral contraceptive
Oral contraceptive